Literature DB >> 27019895

[Percutaneous kyphoplasty for the treatment of osteoporotic vertebral compression fracture with degenerative scoliosis].

Hang-bo Qu, Pei-jian Tong, Wei-feng Ji, Ju Li.   

Abstract

OBJECTIVE: To evaluate the therapeutic effects of percutaneous kyphoplasty (PKP) for the treatment of osteoporotic vertebral compression fracture (OVCF) with degenerative scoliosis.
METHODS: From March 2009 to March 2014,121 patients undergoing PKP for the treatment of osteoporotic vertebral compression fracture (OVCF) with degenerative scoliosis were retrospective analyzed. There were 41 males and 80 females,ranging in age from 56 to 92 years with an average of 73.2 years. Preoperative and postoperative 3 d respectively pain visual analogue scale (visual analogue score, VAS) and Oswestry Disability Index assessed pain and functional recovery of patients and preoperative and postoperative 3 d lumbar lordosis, scoliosis Cobb angle were analyzed.
RESULTS: All the patients were followed up, and the duration ranged from 6 to 24 months, with a mean time of 11 months. All the patients achieved success in operation without serious complications. The operation time ranged from 30 to 65 min with an average of 42.2 min. Local leakage of bone cement was not found in canal. The VAS and Oswestry Disability Index at the 3rd day after operation decreased significantly compared with those of the preoperative (P < 0.05), and the lumbar lordosis and scoliosis Cobb angle also improved significantly compared with those of the preoperative (P < 0.05).
CONCLUSION: Percutaneous kyphoplasty (PKP) for the treatment of thoracolumbar scoliosis osteoporotic fracture can significantly improve patients spinal deformity, pain relief, which is worth of recommending.

Entities:  

Mesh:

Year:  2016        PMID: 27019895

Source DB:  PubMed          Journal:  Zhongguo Gu Shang        ISSN: 1003-0034


  1 in total

1.  Clinical efficacy of PVP and PKP in the treatment of OVCFs after bilateral resection of ovarian cancer.

Authors:  Shaoqian Wang; Hui Wang; Lei Niu
Journal:  Oncol Lett       Date:  2018-05-07       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.